SafePolyMed

SafePolyMed: Innovation for safer medication use

Adverse drug reactions are a major health risk. In the EU-funded project SafePolyMed we developed the Medication Management Center (MMC), a tool that helps patients and healthcare professionals document and analyse complex drug interactions and genetic influences. Using artificial intelligence, machine learning and pharmacokinetic modelling, risks are detected early and personalised therapy decisions are supported. We tested the MMC in a proof-of-concept study with 120 patients. The study is complete and the analysis is under way.

Key facts

  • Duration: 06/2022 to 08/2026
  • Coordination: Saarland University
  • Funder: European Union, Horizon Europe (Grant Agreement 101057639)
  • Links: Project website, YouTube channel

Publications

  • Gepp SC, Schera F, Marok F, … Lehr T, Kiefer S. The SafePolyMed Medication Management Center: A patient-centered platform for improving safety in polypharmacy. Curr Dir Biomed Eng. 2026;12(1):163-166. doi:10.1515/cdbme-2026-0142
  • Dette CMU, Alberg V, Rüdesheim S, … Schwab M, Lehr T. Advancing rare disease therapeutics through digital twins: Opportunities in drug development and precision dosing. Comput Struct Biotechnol J. 2025;28:592-608. doi:10.1016/j.csbj.2025.11.047
  • Rüdesheim S, Loer HLH, Feick D, … Schwab M, Lehr T. A comprehensive CYP2D6 drug-drug-gene interaction network for application in precision dosing and drug development. Clin Pharmacol Ther. 2025;117(6):1718-1731. doi:10.1002/cpt.3604
  • Kovar C, Loer HLH, Rüdesheim S, … Schwab M, Lehr T. A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions. CPT Pharmacometrics Syst Pharmacol. 2024;13(7):1144-1159. doi:10.1002/psp4.13146
  • Loer HLH, Kovar C, Rüdesheim S, … Schwab M, Lehr T. Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions. CPT Pharmacometrics Syst Pharmacol. 2024;13(6):926-940. doi:10.1002/psp4.13127

Posters

  • Dette CMU, Marok FZ, Alberg V, … Remke M, Lehr T. Pediatric PBPK modeling to support therapeutic drug monitoring of methotrexate. PAGE 2026, Dubrovnik. Abstract 11891
  • Marok FZ, Wojtyniak D, Rüdesheim S, Fuhr LM, Schwab M, Lehr T. Parent-metabolite physiologically based pharmacokinetic modeling of mirtazapine during drug-drug- and drug-gene-interactions. PAGE 2024, Rome. Abstract 11047
  • Fuhr LM, Marok FZ, Lehr T. Physiologically based pharmacokinetic modeling of amitriptyline and its active metabolite nortriptyline to investigate CYP2D6 and CYP2C19 mediated drug-drug and drug-gene interactions. PAGE 2024, Rome. Abstract 11211